Skip to content

Impact of inravenous lidocaine on median effective dose of sufentanil for patients undergoing laryngoscopy

Impact of inravenous lidocaine on median effective dose of sufentanil for patients undergoing laryngoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064402
Enrollment
Unknown
Registered
2022-10-06
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vocal cord polyps

Interventions

Experimental group:Different doses of sufentanil

Sponsors

Yichang Central People's Hospital of Hubei Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. ASA I or II; 3. Estimated anesthesia operation time <=120min; 4. BMI 14~23.9kg/m^2.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of opioid allergy; 2. Analgesics, sedatives, antiemetics and antipruritic drugs were used 24 hours before surgery; 3. Patients with body temperature higher than 38°C or with symptoms of acute upper respiratory tract infection within 24 hours before surgery; 4. Patients with a history of bronchial asthma; 5. Patients diagnosed with moderate to severe sleep apnea syndrome before surgery; 6. Patients with difficult airway or a history of abnormal anesthesia recovery in the preoperative assessment; 7. Renal function damage (BUN and or Cr> the upper limit of normal); 8. Liver function damage (ALT and or AST>1.5 times the upper limit of normal); 9. Patients with a history of severe head trauma and intracranial hypertension within 6 months; 10. Patients with mental or neurological diseases, or patients who cannot correctly express their wishes; 11. Patients with a history of taking long-term sedative and analgesic drugs or monoamine oxidase inhibitors; 12. Expected surgical blood loss greater than 100ml; 13. Those who have participated in clinical trials of other drugs within the past month; 14. Patients who cannot be scored by ASA or FLACC for various reasons; 15. Patients who are accompanied by other conditions, and the researchers think that they are not suitable for inclusion; 16. Abnormal breath-holding test; 17. Have not quit smoking within the last half month; 18. Hypertensive patients or those with arrhythmias.

Design outcomes

Primary

MeasureTime frame
The extent of sufentanil induced choking (SIC);Degree of choking induced by extubation (EIC);Score for throat pain;ED50 for EIC;ED50 for SIC;ED50 for throat pain;Hemodynamic parameters within five minutes after induction of intubation;Number of cases with related adverse events;

Secondary

MeasureTime frame
Incidence of analgesic use;Incidence of nausea and vomiting;Time for extubation;

Countries

China

Contacts

Public ContactGong Yuan

Yichang Central People's Hospital

gy-yc@163.com+86 13986746821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026